Nutrisystem.com
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • Support on the Diabetes Journey
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Nutrisystem.com
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

The i-port®

Davida Kruger and KK Patton

The i-port®

Close Encounter - A Profile of a Diabetes Patient and Business Insider

Kelly Close

Close Encounter - A Profile of a Diabetes Patient and Business Insider

ReliOn at Wal-Mart

Bob Guest

ReliOn at Wal-Mart

Januvia Archives

Diabetes and Januvia

Updated 6 days ago
FDA OKs Sale of Combo Drug JANUMET® XR

The FDA has approved US sales of JANUMET® XR, a daily oral treatment for type 2 diabetes that combines sitagliptin and extended-release metformin. The drug is the fourth oral type 2 diabetes treatment introduced by Merck, which also sells JANUVIA, JANUMET, and JUVISYNC.

Comments 0 comments - Feb 6, 2012 - * * * * *

New Type 2 Drug Targets Blood Sugar and Cholesterol

Drug company Merck aims to give people with type 2 diabetes two treatments for the price of one. The new therapy, called Juvisync, was just approved by the US Food and Drug Administration. It's not a radical new treatment, but instead a helpful combination of two familiar standbys: Juvisync unites the active ingredients in blood sugar-lowering Januvia and cholesterol-lowering Zocor in a single tablet.

Comments 0 comments - Dec 10, 2011 - * * * * *

Study Says Byetta and Januvia Do Not Pose Extra Risk for Pancreatitis

A study released in late June has brought some welcome news to the makers of Byetta and Januvia: Users of the two diabetes drugs run no greater risk of developing pancreatitis than people with diabetes who take other drugs. In fact, both drugs seem to put users at slightly less risk for the condition.

Comments 0 comments - Jul 8, 2010 - * * * * *

Januvia Taken Alone May Increase Pancreatic Risks, But Using It With Metformin Removes the Threat

A study of Merck's Januvia (sitagliptin), a drug for patients with type 2 diabetes, has found that its use can lead in some patients to a low-grade form of pancreatitis and an increased risk of pancreatic cancer in the long term. However, the study, conducted at the Larry L. Hillblom Islet Research Center at UCLA, also found that the risks associated with Januvia as a monotherapy are removed when the drug is used in conjunction with metformin (trade name Glucophage). Metformin, a low-cost drug that controls glucose production by the liver, is one of the oldest and most benign standbys in the anti-diabetes arsenal.

Comments 0 comments - May 27, 2009 - * * * * *

Long-Acting Byetta Tops Two Other Diabetes Drugs in Direct Comparison

Results from DURATION-2, a 26-week test comparing the diabetic drugs Januvia, Actos, and experimental long-acting Byetta (Byetta LAR) show that Byetta produced lower A1c's and more weight loss than the other two drugs.

Comments 5 comments - Apr 15, 2009 - * * * * *

Januvia Okayed for Use With Sulfonylureas

Januvia, also known as sitagliptin phosphate, is a DPP-IV inhibitor. It prevents, or inhibits, DPP-IV from inactivating GLP-1. GLP-1 is a naturally produced hormone that increases insulin secretion in response to food.

Comments 1 comment - Nov 20, 2007 - * * *

New Type 2 Drugs Januvia and Byetta Offer Big Benefits
New Type 2 Drugs Januvia and Byetta Offer Big Benefits

The 21st century may be remembered as the time when diabetes became a worldwide epidemic. However, it may also be known as the time when the disease was cured.

Comments 8 comments - May 3, 2007 - * * * * *

JANUVIAâ„¢ Approved in the European Union for the Treatment of Type 2 Diabetes
JANUVIAâ„¢ Approved in the European Union for the Treatment of Type 2 Diabetes

Whitehouse Station, N.J., March 26, 2007 – JANUVIA™ (sitagliptin1), Merck & Co., Inc.'s once-a-day oral treatment for patients with type 2 diabetes, has been granted a license from the European Commission.  JANUVIA now becomes the first and only medication in a new class of drugs known as dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors), which enhance the body’s own ability to lower blood sugar when it is elevated, to be adopted by the European Commission.

Comments 1 comment - Apr 18, 2007 - * * * * *

Oral Meds Research

Starlix Found to Reduce Liver Fat

Comments 0 comments - Sep 1, 2006 - Not Yet Rated

Merck Announces FDA Acceptance of NDA for Januvia

By October of this year, Merck & Co., Inc., expects the FDA to rule on its novel type 2 drug Januvia (sitagliptin phosphate). On February 15, 2006, the FDA accepted Merck’s New Drug Application (NDA) for Januvia for standard review.

Comments 0 comments - May 1, 2006 - Not Yet Rated

Next Page »  
Nutrisystem.com
©1991-2012 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.